LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

NCT02964247 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding the medication liraglutide to a standard diabetes treatment (SGLT2 inhibitors) helps lower blood sugar levels in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 303 people

Who can join Ages 18+ · all sexes

Timeline Started 2017-03 · est. completion 2018-05

Where 82 sites · Brazil, India, Israel, Puerto Rico, Russia, United Arab Emirates, United States

What this study is testing ClinicalTrials.gov NCT02964247 ↗

Description as written by the study sponsor.

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

Treatments tested

liraglutide Drug

Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
placebo Drug

Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02964247 ↗